Envestnet Portfolio Solutions Inc. Buys 2,518 Shares of Enovis Co. (NYSE:ENOV)

Envestnet Portfolio Solutions Inc. boosted its position in shares of Enovis Co. (NYSE:ENOV) by 19.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,433 shares of the company’s stock after buying an additional 2,518 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Enovis were worth $677,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ENOV. Amalgamated Bank increased its holdings in shares of Enovis by 1.0% in the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock worth $1,136,000 after buying an additional 264 shares during the last quarter. Pinnacle Bancorp Inc. lifted its holdings in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after acquiring an additional 300 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Enovis by 2.6% during the 4th quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock worth $711,000 after purchasing an additional 414 shares during the period. UMB Bank n.a. grew its holdings in Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares during the last quarter. Finally, New York State Teachers Retirement System raised its position in Enovis by 3.5% in the 4th quarter. New York State Teachers Retirement System now owns 13,538 shares of the company’s stock worth $594,000 after purchasing an additional 457 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Trading Up 2.4 %

ENOV stock opened at $40.01 on Tuesday. Enovis Co. has a 12 month low of $35.14 and a 12 month high of $62.79. The firm’s 50-day moving average is $42.61 and its 200 day moving average is $43.47. The company has a market capitalization of $2.28 billion, a PE ratio of -18.27 and a beta of 2.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last issued its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. On average, research analysts anticipate that Enovis Co. will post 2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC dropped their target price on Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 27th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.